KTTA widens losses as PAS-004 spending rises and FDA clears Phase 2 trial
KTTA's third-quarter losses widened on higher PAS-004 spending. The company holds $41.2M in cash and equivalents, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, KTTA's losses widened in the third quarter as the company increased clinical and regulatory spending on its PAS-004 drug candidate. Cash and equivalents stood at $41.2M, which the company estimates will fund operations for at least 12 months. The FDA has cleared a Phase 2 trial of PAS-004 for cutaneous neurofibromas associated with NF1.
why it matters
Two factors matter for investors: rising spending shortens the runway, while the FDA clearance opens the way to new clinical data. The impact is limited to one company, but the story is typical of early-stage biotechs that depend on outside capital.
market impact
KTTA shares: higher spending and losses weigh on the stock, while FDA clearance supports interest.
- KTTA shares mixed — higher spending and losses weigh on the stock, while FDA clearance supports interest
tags
instruments
sources
- KTTA: PAS-004 investment accelerated, widening losses as FDA cleared a Phase 2 NF1 skin-tumor trial — TradingView, 13 November 2026 at 22:18 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗